ID   TCC-Y/sr
AC   CVCL_D3Z5
SY   TCC-Y / sr
DR   Wikidata; Q127384378
RX   Patent=WO2004094628A1;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, Japanese National Institute of Bioscience and Human-Technology, Agency of Industrial Science and Technology; FERM BP-8531.
CC   Population: Japanese.
CC   Doubling time: 34 +- 4 hours (Patent=WO2004094628A1).
CC   Selected for resistance to: ChEBI; CHEBI_45783; Imatinib (Gleevec; STI571).
CC   Sequence variation: Gene fusion; HGNC; HGNC:76; ABL1 + HGNC; HGNC:1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:76; ABL1; Simple; p.Thr315Ile (c.944C>T) (c.1001C>T); ClinVar=VCV000012624; Zygosity=Unspecified (Patent=WO2004094628A1).
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
DI   NCIt; C114819; Adult B acute lymphoblastic leukemia with t(9;22)(q34.1;q11.2) BCR-ABL1
DI   ORDO; Orphanet_585909; B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_D3Z4 ! TCC-Y
SX   Sex unspecified
AG   Adult
CA   Cancer cell line
DT   Created: 30-01-24; Last updated: 19-12-24; Version: 3
//
RX   Patent=WO2004094628A1;
RA   Sato Y., Nagao H.;
RT   "Imanitib-resistant Philadelphia chromosome-positive human acute
RT   lymphocytic leukemic cell line and utilization thereof.";
RL   Patent number WO2004094628A1, 04-Nov-2004.
//